WURMLINGEN – Companion Spine LLC, the French-American spine implant surgery specialist, announced on Tuesday the completion of its acquisition of the Paradigm Spine business globally from Xtant Medical Holdings, Inc. (NYSE: XTNT).
The deal includes the flagship Coflex® Interlaminar Stabilization® device and CoFix® fusion system, along with all related subsidiaries and global business activities.
The combined entity establishes what the company claims is the largest global footprint in Posterior Dynamic Solutions™ for treating degenerative spine diseases. Paradigm Spine will retain its branding and operational base in Germany. Leadership will be led by Anthony G. Viscogliosi as Executive Chairman and CEO of Companion Spine.
“This acquisition expands our mission to treat spine pain, positioning us to meet demand in the U.S. and high-growth international markets,” said Viscogliosi. He framed the move as a reunion, with Paradigm Spine—previously part of the Viscogliosi Brothers portfolio—returning as “the prodigal son.”
The transaction aims to leverage Paradigm Spine’s two-decade legacy of U.S. FDA Premarket Approval (PMA) products with Companion Spine’s portfolio, which includes the DIAM™ Spinal Stabilization System. The combined suite targets the full spectrum of lumbar spinal stenosis (LSS) and degenerative disc disease (DDD).
“We are providing enhancements for our distributors as we substantially expand our growth on a global scale,” said Enrico Sangiorgio, named Executive Vice President International of Paradigm Spine and General Manager of Companion Spine outside the U.S.
For Xtant Medical, the sale allows a strategic refocus on its core orthobiologics and chronic care business while reducing debt. “These motion preservation technologies will get the kind of focus only the Viscogliosi Brothers and Companion Spine can provide,” said Xtant CEO Sean Browne.
Companion Spine’s senior lender is Innovatus Capital Partners. The company was advised by Dorsey & Whitney LLP and a suite of specialist firms. Xtant Medical was advised by Fox Rothschild LLP and LifeSci Partners.